Evidence map›Paper›PMID 37312837›Full record

ArticleACS medicinal chemistry letters2023

Discovery of Novel, Selective Prostaglandin EP4 Receptor Antagonists with Efficacy in Cancer Models.

Debasis Das, Dandan Qiao, Zhonghe Liu, Lingzhi Xie, Yong Li, Jingbing Wang, Jianhe Jia, Yuxi Cao, Jian Hong

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Unique/Rapid Feedback Mechanisms of PGDBioEssays : news and reviews in molecular, cellular and developmental biology · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Debasis DasArromax Pharmatech Co. Ltd. Sangtiandao Innovation Park, No. 1 Huayun Road, SIP, Suzhou 215123, P. R. China.ORCID https://orcid.org/0000-0002-4018-0793
Dandan QiaoArromax Pharmatech Co. Ltd. Sangtiandao Innovation Park, No. 1 Huayun Road, SIP, Suzhou 215123, P. R. China.
Zhonghe LiuArromax Pharmatech Co. Ltd. Sangtiandao Innovation Park, No. 1 Huayun Road, SIP, Suzhou 215123, P. R. China.
Lingzhi XieArromax Pharmatech Co. Ltd. Sangtiandao Innovation Park, No. 1 Huayun Road, SIP, Suzhou 215123, P. R. China.
Yong LiArromax Pharmatech Co. Ltd. Sangtiandao Innovation Park, No. 1 Huayun Road, SIP, Suzhou 215123, P. R. China.
Jingbing WangArromax Pharmatech Co. Ltd. Sangtiandao Innovation Park, No. 1 Huayun Road, SIP, Suzhou 215123, P. R. China.
Jianhe JiaArromax Pharmatech Co. Ltd. Sangtiandao Innovation Park, No. 1 Huayun Road, SIP, Suzhou 215123, P. R. China.
Yuxi CaoArromax Pharmatech Co. Ltd. Sangtiandao Innovation Park, No. 1 Huayun Road, SIP, Suzhou 215123, P. R. China.
Jian HongArromax Pharmatech Co. Ltd. Sangtiandao Innovation Park, No. 1 Huayun Road, SIP, Suzhou 215123, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostaglandin E2 (PGE

Identifiers

PMID37312837
PMCPMC10258902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.